NCT05645055 Biologics for Stricturing Crohn's Diseases
| NCT ID | NCT05645055 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jinling Hospital, China |
| Condition | The Efficacy of Biologics for Stricturing Crohn's Diseases |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2021-01-01 |
| Primary Completion | 2024-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2021-01-01 with a primary completion date of 2024-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Recent researches have reported that biologics might be also effective for stricturing CD. However, the data were largely retrospective. Prospective studied are needed for evaluate the efficacy of biologics for stricturing Crohn's diseases.
Eligibility Criteria
Inclusion Criteria: * patients with stricturing Crohn's diseases * no surgical indication * patients with asymptomatic penetrating diseases * written consent acquired Exclusion Criteria: * patients with surgical indication * patients with symptomatic penetrating diseases * contraindication of biologics * anticipating other trial
Contact & Investigator
Weiming wm Zhu, Ph.D.
PRINCIPAL INVESTIGATOR
Jinling Hospital, China
Frequently Asked Questions
Who can join the NCT05645055 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 65 Years, studying The Efficacy of Biologics for Stricturing Crohn's Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05645055 currently recruiting?
Yes, NCT05645055 is actively recruiting participants. Contact the research team at juwiming@nju.edu.cn for enrollment information.
Where is the NCT05645055 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT05645055 clinical trial?
NCT05645055 is sponsored by Jinling Hospital, China. The principal investigator is Weiming wm Zhu, Ph.D. at Jinling Hospital, China. The trial plans to enroll 200 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.